Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 12, 2016 - Issue 12
Submit an article Journal homepage
352
Views
21
CrossRef citations to date
0
Altmetric
Review

Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines

T. J. VreelandDepartment of Surgery, Womack Army Medical Center, Fort Bragg, NC, USACorrespondence[email protected]
View further author information
,
G. T. CliftonDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
G. S. HerbertDepartment of Surgery, Brooke Army Medical Center, Fort Sam Houston, TX, USAView further author information
,
D. F. HaleDepartment of Surgery, Brooke Army Medical Center, Fort Sam Houston, TX, USAView further author information
,
D. O. JacksonDepartment of Surgery, Brooke Army Medical Center, Fort Sam Houston, TX, USAView further author information
,
J. S. BerryDepartment of Surgery, Brooke Army Medical Center, Fort Sam Houston, TX, USAView further author information
&
G. E. PeoplesDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA;Cancer Vaccine Development Program, San Antonio, TX and Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USACorrespondence[email protected]
View further author information
 show all
Pages 1347-1357 | Received 13 Apr 2016, Accepted 13 Jun 2016, Published online: 28 Jun 2016

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Patrick M. McCarthy, G. Travis Clifton, Timothy J. Vreeland, Alexandra M. Adams, Anne E. O’Shea & George E. Peoples. (2021) AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence. Expert Opinion on Investigational Drugs 30:1, pages 5-11.
Read now

Articles from other publishers (20)

Robert Connor Chick, Andrew J. Gunderson, Shafia Rahman & Jordan M. Cloyd. (2023) Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results. Cancers 15:15, pages 3967.
Crossref
Elizabeth Lee Carpenter, Spencer Van Decar, Alexandra M Adams, Anne E O’Shea, Patrick McCarthy, Robert Connor Chick, Guy Travis Clifton, Timothy Vreeland, Franklin A Valdera, Ankur Tiwari, Diane Hale, Phillip Kemp Bohan, Annelies Hickerson, Todd Smolinsky, Katryna Thomas, Jessica Cindass, John Hyngstrom, Adam C Berger, James Jakub, Jeffrey J Sussman, Montaser F Shaheen, Xianzhong Yu, Thomas E Wagner, Mark Faries & George E Peoples. (2023) Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis. Journal for ImmunoTherapy of Cancer 11:8, pages e006665.
Crossref
Alexandra M. Adams, Elizabeth L. Carpenter, Guy T. Clifton, Timothy J. Vreeland, Robert C. Chick, Anne E. O’Shea, Patrick M. McCarthy, Phillip M. Kemp Bohan, Annelies T. Hickerson, Franklin A. Valdera, Ankur Tiwari, Diane F. Hale, John R. Hyngstrom, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Montaser F. Shaheen, Xianzhong Yu, Thomas E. Wagner, Mark B. Faries & George E. Peoples. (2022) Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial. Cancer Immunology, Immunotherapy 72:3, pages 697-705.
Crossref
Francesco Pasqualetti & Sofia Zanotti. (2023) Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination. British Journal of Cancer.
Crossref
Cristina Bayó, Gerhard Jung, Marta Español-Rego, Francesc Balaguer & Daniel Benitez-Ribas. (2021) Vaccines for Non-Viral Cancer Prevention. International Journal of Molecular Sciences 22:20, pages 10900.
Crossref
Timothy J. Vreeland, Guy T. Clifton, Diane F. Hale, Robert C. Chick, Annelies T. Hickerson, Jessica L. Cindass, Alexandra M. Adams, Phillip M. Kemp Bohan, Robert H. I. Andtbacka, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Alicia M. Terando, Thomas Wagner, George E. Peoples & Mark B. Faries. (2021) A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis. Annals of Surgical Oncology 28:11, pages 6126-6137.
Crossref
Irina Alekseenko, Alexey Kuzmich, Liya Kondratyeva, Sofia Kondratieva, Victor Pleshkan & Eugene Sverdlov. (2021) Step-by-Step Immune Activation for Suicide Gene Therapy Reinforcement. International Journal of Molecular Sciences 22:17, pages 9376.
Crossref
Alexandra M. Adams, Robert C. Chick, Timothy J. Vreeland, Guy T. Clifton, Diane F. Hale, Patrick M. McCarthy, Anne E. O’Shea, Phillip M Kemp Bohan, Annelies T. Hickerson, Hyohyun Park, Amanda JoEllen Sloan, John Hyngstrom, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Montaser Shaheen, Thomas Wagner, Mark B. Faries & George E. Peoples. (2021) Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma. Melanoma Research Publish Ahead of Print.
Crossref
Robert C. Chick, Mark B. Faries, Diane F. Hale, Phillip M Kemp Bohan, Annelies T. Hickerson, Timothy J. Vreeland, John W. MyersIIIIII, Jessica L. Cindass, Tommy A. BrownIIII, John Hyngstrom, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Montaser Shaheen, Guy T. Clifton, Hyohyun Park, Amanda J. Sloan, Thomas Wagner & George E. Peoples. (2021) Multi‐institutional, prospective, randomized, double‐blind, placebo‐controlled phase IIb trial of the tumor lysate, particle‐loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high‐risk melanoma patients: A subgroup analysis. Cancer Medicine.
Crossref
Constantin N. Baxevanis, Sotirios P. Fortis, Alexandros Ardavanis & Sonia A. Perez. (2020) Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design. Cancers 12:10, pages 2908.
Crossref
María José Godoy-Calderón, Eglys González-Marcano, Jeismar Carballo & Ana Federica Convit. (2019) Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment. Oncotarget 10:61, pages 6546-6560.
Crossref
Robert A. Belderbos, Joachim G.J.V. Aerts & Heleen Vroman. (2019) Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. Molecular Therapy - Oncolytics 13, pages 67-81.
Crossref
Robin L. Anderson, Theo Balasas, Juliana Callaghan, R. Charles Coombes, Jeff Evans, Jacqueline A. Hall, Sally Kinrade, David Jones, Paul S. Jones, Rob Jones, John F. Marshall, Maria Beatrice Panico, Jacqui A. Shaw, Patricia S. Steeg, Mark Sullivan, Warwick Tong, Andrew D. Westwell & James W. A. Ritchie. (2018) A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology 16:3, pages 185-204.
Crossref
Robert O. Dillman, Andrew N. Cornforth, Gabriel I. Nistor, Edward F. McClay, Thomas T. Amatruda & Carol Depriest. (2018) Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses. Journal for ImmunoTherapy of Cancer 6:1.
Crossref
Jay A. Berzofsky, Masaki Terabe, Jane B. Trepel, Ira Pastan, David F. Stroncek, John C. Morris & Lauren V. Wood. (2017) Cancer vaccine strategies: translation from mice to human clinical trials. Cancer Immunology, Immunotherapy 67:12, pages 1863-1869.
Crossref
Fang Zheng, Jianzhong Dang, Hongyu Zhang, Fangzhou Xu, Diandian Ba, Bingyu Zhang, Fanjun Cheng, Alfred E. Chang, Max S. Wicha & Qiao Li. (2018) Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model. Journal of Immunotherapy 41:8, pages 361-368.
Crossref
Timothy J. Vreeland, Jennifer K. Litton, Na Qiao, Anne V. Philips, Gheath Alatrash, Diane F. Hale, Doreen O. Jackson, Kaitlin M. Peace, Julia M. Greene, John S. Berry, Guy T. Clifton, George E. Peoples & Elizabeth A. Mittendorf. (2018) Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39’: An analysis of safety and immune response. Clinical Immunology 192, pages 6-13.
Crossref
E. D. Sverdlov. (2018) Unsolvable Problems of Biology: It Is Impossible to Create Two Identical Organisms, to Defeat Cancer, or to Map Organisms onto Their Genomes. Biochemistry (Moscow) 83:4, pages 370-380.
Crossref
Olivera J. Finn. (2017) The dawn of vaccines for cancer prevention. Nature Reviews Immunology 18:3, pages 183-194.
Crossref
B. Bonavida & S. Chouaib. (2017) Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance. Annals of Oncology 28:3, pages 457-467.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.